Psych Hospital Operator Acadia Healthcare Downgraded As It Braces For Medicaid Cuts

Acadia Healthcare (ACHC) was downgraded by BofA Securities to Neutral from Buy, with a price target reduction to $25, primarily due to anticipated headwinds from Medicaid state-directed payment program cuts post-2028 and recent same-store volume deceleration. This downgrade occurred despite Acadia reporting Q2 adjusted EPS of $0.83 and sales of $869.23 million, both exceeding consensus estimates. However, the company subsequently lowered its fiscal 2025 adjusted EPS guidance to $2.45-$2.65 and narrowed sales guidance, contributing to an 8.48% stock decline. BofA acknowledges potential volume recovery from significant bed expansion (12% in 2024, 8% in 2025) as a mitigant before the long-term Medicaid impact.

Analysis

Acadia Healthcare (ACHC) faces a challenged outlook despite a strong second quarter performance, as evidenced by a BofA Securities downgrade to Neutral from Buy and a price target cut to $25 from $27. The primary driver for the downgrade is a significant long-term headwind from anticipated cuts to Medicaid state-directed payment programs beginning in 2028. This long-term regulatory risk overshadowed a Q2 earnings beat, where adjusted EPS of 83 cents surpassed the 68-cent consensus, and sales grew 9.2% year-over-year to $869 million, also exceeding estimates. However, the company's own revised guidance lends credence to a more cautious stance; fiscal 2025 adjusted EPS guidance was lowered to $2.45-$2.65, below the $2.67 consensus, and sales guidance was narrowed. Near-term operational pressures are also evident, with same-store volumes decelerating due to site-specific legal issues and payor pressure on admissions. The market reacted decisively to the negative catalysts, with the stock falling 8.48%. A key mitigating factor is the company's aggressive capacity expansion, with a 12% bed increase in 2024 and a further 8% planned for 2025, which is expected to drive a medium-term volume rebound before the Medicaid cuts materialize.

Key Decisions for Investors

• Investors should closely monitor any policy developments concerning Medicaid state-directed payment programs, as the anticipated cuts post-2028 represent the primary long-term risk factor cited for the downgrade.
• It is prudent to weigh the company's medium-term volume growth potential, driven by a 12% bed expansion in 2024, against the lowered FY25 earnings guidance and the significant long-term regulatory overhang.
• Given the stock's 8.48% decline and the downgrade to Neutral, investors may consider the current price as reflecting a balance between near-term operational execution and distant but impactful regulatory risks, warranting a cautious hold or a 'wait-and-see' approach for new positions.
• Key performance indicators to watch are the ramp-up of new bed capacity and improvements in same-store volume, which will signal if the company can effectively counteract the payor pressures and facility-specific disruptions noted in the report.